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When an antibody is detected, its specificity should be determined 
and its likely clinical significance should be assessed. When one 
antibody has been identified, it becomes necessary to confirm 
the presence of additional significant antibodies to ensure that 
compatible blood is provided to the patient. To perform this 
confirmation, specific reagent red blood cells (RBCs) are selected; 
these are called selected cells. Though the most common use of 
selected cells is for antibody confirmation, they can also be used 
for several other immunohematologic applications. In a developing 
country like India, the performance of antibody screening for 
unexpected antibodies on a routine basis is a comparatively 
new phenomenon, and those laboratories performing advanced 
immunohematologic testing would need to use selected 
cells to arrive at an accurate conclusion. This report defines 
selected cells and enumerates sources of these RBCs. Detailed 
immunohematologic applications are discussed with applicable 
case studies. Immunohematology 2017;33:27–35.
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When an unexpected antibody is detected in the antibody 
screening procedure, its specificity should be determined 
and its likely clinical significance should be assessed.1 The 
presence of preexisting unexpected red blood cell (RBC) 
antibody(ies) in the patient’s medical records makes it all the 
more important to perform testing to identify or exclude the 
presence of additional antibodies (also referred to as the rule-
in/rule-out process). Per the British Committee for Standards 
in Haematology (BSCH) guidelines and the AABB Standards 
for Immunohematology Reference Laboratories, an antibody 
specificity should be assigned only when the patient’s plasma is 
reactive with at least two examples of reagent RBCs expressing 
the corresponding antigen and is nonreactive with at least two 
examples of reagent RBCs lacking this antigen.2,3 When one 
antibody has been identified, it becomes necessary to test for 
the presence of additional significant antibody(ies). For this 
confirmation, specific reagent RBCs are selected, and these 
are called selected cells. It is analogous to having a differential 
diagnosis in a clinical setting that is confirmed after routine 
and specialized investigations with a method called “approach-
to-diagnosis.” Though the most common use of selected cells 
is for antibody confirmation, they can also be used for other 
immunohematologic applications. In a developing country like 
India, the use of antibody screening for unexpected antibodies 
on a routine basis is a comparatively new phenomenon, and 
those laboratories performing advanced immunohematologic 
testing would need to use selected cells to arrive at an accurate 
conclusion.4 In this report, we provide definition, sources, and 
applications of selected cells along with real-life illustrations 
of their use.
Definition
Selected cells are RBCs chosen for use based on their 
antigenic make-up. They are most often used to include 
and/or exclude clinically significant antibodies to ensure that 
the patient receives compatible RBC units. If the patient’s 
medical chart reveals previous identification of historical 
antibody(ies), all significant antibody specificities should be 
honored, and RBCs lacking the corresponding antigen can be 
used to assist in the identification of other antibodies.
Characteristics of Selected Cells
• Selected cells are RBCs chosen because they express 
some specific antigen(s) and lack others.
• Each selected cell is blood group O or ABO-compatible 
with the sample being tested.
• Each selected cell’s antigenic make-up has been 
determined.
Sources of Selected Cells
Selected cells can be chosen from:
• Antibody screening cells
• Antibody identification panels
• Extended-cell antibody identification panels (i.e., a 
panel with more than 11 cells)
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• Recently expired screening or panel cells
• Crossmatched blood donor units
• Phenotyped blood donor units
• Frozen rare RBC inventory
Antibody Screening Cells
Antibody detection testing is typically performed as part 
of pre-transfusion testing. Commercially available reagent 
screening RBCs have combinations of Rh-phenotyped R1R1 
(DCCee), R2R2 (DccEE), and rr (ccee) cells that can act as 
selected cells for confirmation and/or exclusion of common 
Rh antibodies. These cells may have double-dose expression 
of other common antigens (K, k, Fya, Fyb, Jka, Jkb, S, s, M, N, 
P1, Lea, and Leb) and can be used as selected cells to identify or 
exclude these respective antibodies.
Antibody Identification Panel
An antibody identification panel is intended for use in the 
identification of unexpected RBC antibodies in a sample. This 
panel consists of suspensions of group O RBCs from eight or 
more donors (commonly 11). Typically, each panel includes 
RBCs with one example each of phenotypes R1R1 (DCCee), 
R1wR1 (D[C]CwCee), R2R2 (DccEE), r′r (CCee), and r″r (ccEE), 
and at least three examples of the phenotype rr (ccee). The 
panel also includes at least one donor RBC that is K+, and, 
collectively, RBCs with double-dose expression of other 
antigens as those on screening cells.2
Extended-Cell Antibody Identification Panel
One important limitation of the antibody identification 
panel is that it sometimes does not permit the identification 
of multiple antibodies; for example, varied reaction strengths 
may occur in the presence of multiple antibodies, making 
interpretation of the results challenging. Many manufacturers 
also provide extended-cell panels that contain examples of 
uncommon phenotypes. Ortho Clinical Diagnostics India 
Private Limited in Mumbai, India, offers a primary 11-cell 
panel, Panel A, and an extended-cell panel, Panel B. Immucor 
India Private Limited in Delhi, India, provides Panocell-20, 
which contains 20 reagent RBCs, 9 of which constitute the 
extended-cell panel. Typically, extended-cell panels contain 
R2R2 RBCs, which help in confirming anti-e, k– RBCs to 
help in confirming anti-k, and other cells with uncommon 
phenotypes, such as RzR1 and R2r. 
Use of these extended-cell panels as selected cells increases 
the probability of being able to identify multiple antibodies or 
an antibody against a high-prevalence antigen. Laboratories 
should define quality control parameters for checking the 
reactivity of expired panel cells.
Recently Expired Screening or Panel Cells
Reactivity of reagent RBCs may decrease with time due 
to the deterioration of some RBC antigens. The rate at which 
this antigen reactivity is lost depends on individual donor 
characteristics, the specific antigen, and storage conditions.5–7 
Consequently, as per the manufacturer’s instructions, reagent 
RBCs should not be used after their expiration date.
Our center in India uses reagent RBCs beyond their 
expiration date as an additional source of selected cells for 
antibody identification when appropriate in-date reagent RBCs 
are not available; quality control and validation for such use 
of these cells is in accordance with the institutional Standard 
Operating Procedure (SOP). Each blood center should develop 
and follow a policy and procedure for use of expired reagent 
panel RBCs as a source of selected cells; quality control and 
allowed expiration date should be established according to 
BSCH and/or AABB standards, as applicable. Thus, expired 
reagent RBCs can be a good and readily available source of 
selected cells.5–7
Note oN Quality CoNtrol 
All reagent RBCs should be checked prior to use for signs 
of deterioration and/or bacterial contamination, such as 
hemolysis, darkening of the RBCs, and spontaneous clumping. 
Testing these reagent cells using examples of weak antibodies 
can be performed to ensure sensitivity of the test procedure and 
the integrity of antigen expression of the reagent RBCs during 
storage. Testing weak anti-D (containing anti-D at a level of 
less than 0.1 IU/mL) with single-dose D+ cells (R1r or R2r) and 
weak anti-Fya with Fy(a+b+) cells is recommended in BSCH 
guidelines for quality check of reagent RBCs.2 In addition, at 
our center, we perform a quality check of expired panel RBCs 
on each day of use by testing a cell lacking an antigen (negative 
control) and a cell expressing an antigen known to deteriorate 
quickly (positive control).
Crossmatched Blood Donor Units
Crossmatch-compatible and crossmatch-incompatible 
units can act as selected cells for confirmation or exclusion of 
antibodies. 
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Case study 1
A 49-year-old man diagnosed with end-stage liver disease 
was scheduled for liver transplant with a request for 11 units of 
RBCs. The immunohematology laboratory received a sample 
for pre-transfusion testing—namely, for blood type, antibody 
detection, and crossmatch. On immunohematologic studies, 
anti-c and anti-E were identified. RBC units that were c– 
and E– were crossmatched with the patient’s serum using 
antihuman globulin (AHG). Some units were compatible and 
some were incompatible, suggesting the presence of another 
unexpected antibody.8
Results
Phenotyping of all compatible and incompatible units 
was performed for Fy, Jk, S, and s antigens. All compatible 
units were found to be c−, E−, Fy(b−); incompatible units were 
c−, E−, Fy(b+), suggesting that the third antibody was anti-
Fyb (Table 1). This finding was further confirmed by treating 
the RBCs of the incompatible c−, E−, Fy(b+) units with 
enzyme (Liquipap, Tulip Diagnostics, Goa, India) and then 
crossmatching with the patient’s serum. The enzyme-treated 
RBCs were now compatible with the patient’s serum because 
Fyb was denatured by the enzyme. The patient’s RBCs typed 
as Fy(b–), which was the final step in confirming the presence 
of anti-Fyb.
Discussion
In this case, anti-c and anti-E were identified initially 
using the 11-cell identification panel, but anti-Fyb was missed. 
Anti-Fyb was identified later, at the time of crossmatching c– 
and E– units. The RBCs of the crossmatch-compatible and 
crossmatch-incompatible units acted as selected cells in this 
case.
Anti-Fyb was not identified initially, possibly because of 
loss of Fyb (as it is a labile antigen) from the reagent RBCs, 
since they were towards the end of their recommended storage 
period, or because the antibody was below the detectable level 
with the method used. Fya and Fyb tend to elute from RBCs 
stored in low pH, low-ionic-strength medium, after prolonged 
storage.9 The practice of using appropriate controls (weak 
anti-D and weak anti-Fya, as described previously) for in-date 
reagent RBCs began thereafter at our institution.
Table 1. Case Study 1: Results of crossmatch-compatible and crossmatch-incompatible RBC units used as selected cells for antibody 
identification
Test results
Unit number c E Fya Fyb S s Jka Jkb IAT Papain-IAT
28299 0 0 + 0 + + + 0 Compatible NT
28314 0 0 + 0 + + + + Compatible NT
28319 0 0 + 0 + + + 0 Compatible NT
28253 0 0 + 0 + + + 0 Compatible NT
28271 0 0 + 0 + + + + Compatible NT
28143 0 0 + 0 + + + + Compatible NT
28204 0 0 0 + + + + 0 Incompatible Compatible
28278 0 0 + + + + + + Incompatible Compatible
28300 0 0 0 + + + + 0 Incompatible Compatible
28760 0 0 + + + + + 0 Incompatible Compatible
RBC = red blood cell; IAT = indirect antiglobulin test; NT = not tested.
Considerations When Choosing Selected Cells
Choose the selected cells conservatively. Choose cells that 
can help rule out more than one antibody to help conserve 
reagents and time. Whenever possible, choose selected cells 
that have a strong expression of the antigen being tested (i.e., 
RBCs with apparent double-dose antigen expression).
Applications of Selected Cells
Four important applications of selected cells are:
• Identification of multiple antibodies
• Identification of additional antibodies in patients with 
known alloantibodies
• Determination of antibody titer in isoimmunized 
pregnant women with multiple antibodies
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• Identification of underlying alloantibodies by differential 
adsorption in patients with warm autoimmune 
hemolytic anemia (WAIHA)
Identification of Multiple Antibodies
Sometimes, the initial antibody identification panel does 
not reveal a clear-cut specificity. When multiple antibodies 
(specificities) are suspected by the rule-in/rule-out process, 
additional testing is needed. Perhaps the simplest next step is 
to test with selected cells. 
Case study 2
A 33-year-old woman was admitted to the gynecology 
department with atypical adenomatous hyperplasia for a 
dilation and curettage procedure. She had a history of receiving 
2 units of RBCs 1 year earlier for vaginal bleeding. Her 
hematocrit on admission was 21.3 percent (normal for females 
>36%). Two RBC units were ordered by her gynecologist.
Results
Her blood type was group B, D+, and her pre-transfusion 
antibody detection test was positive. Using an 11-cell antibody 
identification panel, there was no clear-cut specificity, 
suggesting multiple antibodies (Table 2). After performing the 
rule-in/rule-out process, three specificities were not excluded: 
anti-E, anti-Fya, and anti-Jkb. Selected cells were chosen 
from a recently expired panel for differentiation between the 
antibodies (Table 3). Anti-E was eliminated by selected cell 
number 7, and anti-Fya was eliminated by selected cell number 
9. The positive reaction in selected cell number 3 suggested the 
presence of anti-Jkb in the sample.
Discussion
This case shows the use of selected cells in the confirmation 
and elimination of antibodies when multiple specificities were 
suspected. An expired panel (1 month past date) was the 
source of selected cells. The reactivity of the expired RBCs 
was checked with appropriate controls before use, as per our 
center’s SOP. Although low-prevalence antigens, Kpa and Jsa, 
could not be evaluated in this testing, they are rare in incidence, 
as the name suggests, and should be considered as a last resort 
in specificity of exclusion.
Table 2. Case Study 2: Results of 11-cell antibody identification panel
Cell 
no.
Rh Kell Duffy Kidd
Sex-
linked Lewis MNS P Lutheran
Test 
result
Rh D C E c e f Cw V K k Kpa Kpb Jsa Jsb Fya Fyb Jka Jkb Xga Lea Leb S s M N P1 Lua Lub AHG
1 R1r + + 0 + + 0 0 0 0 + 0 + 0 + + + + + + 0 + + + + + + 0 + 1+
2 R1wR1 + + 0 0 + 0 + 0 + + 0 + 0 + 0 + + 0 + 0 0 + 0 + 0 + 0 + 0
3 R2R2 + 0 + + 0 0 0 0 0 + 0 + 0 + + 0 + + + 0 + 0 + 0 + + 0 + 1+
4 R0r + 0 0 + + + 0 + 0 + 0 + 0 + + 0 + + 0 + 0 + + + 0 0 0 + 1+
5 r′r 0 + 0 + + + 0 0 0 + 0 + 0 + 0 0 + 0 0 0 + + + + 0 + 0 + 0
6 r″r 0 0 + + + + 0 0 0 + 0 + 0 + + + 0 + + 0 + 0 + 0 + + 0 + 2+
7 rr 0 0 0 + + + 0 0 + + 0 + 0 + + + + + + 0 + 0 + + + 0 0 + 1+
8 rr 0 0 0 + + + 0 0 0 + 0 + 0 + 0 + + 0 0 + 0 + 0 + + + + + 0
9 r′r″ 0 + + + + + 0 0 0 + 0 + 0 + 0 + + 0 + 0 + 0 + 0 + + 0 + 0
10 rr 0 0 0 + + + 0 0 0 + 0 + 0 + + 0 + + + 0 + + 0 + 0 + 0 + 1+
11 R1r + + 0 + + 0 0 0 0 + 0 + 0 + + + 0 + + 0 + + + + + + 0 + 2+
Patient’s cells 0
AHG = antihuman globulin.
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Identification of Additional Antibodies
When a patient has a known antibody and the technologist 
is attempting to determine if additional antibodies are present, 
selected cells (negative for corresponding antigen of known 
antibody) are the best tool to use. 
Case study 3
A 16-year-old boy with thalassemia intermedia, who 
had received multiple transfusions in the past 15 years from 
a tertiary health care center, relocated to a new city and was 
referred to a primary care center for blood transfusion. At this 
center, he experienced difficulty breathing and pain in his 
abdomen during two transfusions before he was referred to 
our institution.
Results
His tertiary care center records mentioned that he 
was alloimmunized with anti-e. Two units of RBCs were 
prescribed by the hematologist because his hematocrit was 
18.9% (normal for males >41%). His blood type was group O, 
D+ with an unexpected antibody identified as anti-e (Table 
4). Typically, e is present on most panel cells (10 out of 11 
cells were e+). Therefore, three e– selected cells (R2R2) were 
chosen from an extended-cell antibody identification panel for 
testing. On testing these cells with the patient’s serum, one cell 
was positive and the other two were negative, suggesting the 
presence of an additional antibody(ies). After the rule-in/rule-
out process was performed, anti-N was suspected (Table 5). To 
confirm this antibody specificity, at least one more e–, N+ cell 
was required to fulfill the two antigen-positive/two antigen-
negative rule. One more selected cell (cell number 3: e–, N+) 
from an expired panel was chosen and found to be positive 
(Table 6). This result confirmed anti-N (showing dosage) along 
with anti-e in the patient. Positive reactions with double-dose 
cells (M–N+: cell number 15 of an extended-cell panel and cell 
number 3 of an expired identification panel, respectively) and 
negative reactions with single-dose cells (M+N+: cells number 
16 and 17 of the extended-cell panel) confirmed the antibody 
Table 3. Case Study 2: Results of testing with selected cells*
Cell 
no.
Rh Kell Duffy Kidd
Sex-
linked Lewis MNS P Lutheran
Test 
result
Rh D C E c e f Cw V K k Kpa Kpb Jsa Jsb Fya Fyb Jka Jkb Xga Lea Leb S s M N P1 Lua Lub AHG
3 rr 0 0 0 + + 0 0 0 0 + 0 + 0 + + + 0 + + + 0 + 0 0 + + 0 + 3+
7 R2R2 + 0 + + 0 0 0 0 0 + 0 + 0 + 0 + + 0 0 0 + + 0 + 0 0 0 + 0
9 R1R1 + + 0 0 + 0 0 0 + + 0 + 0 + + 0 + 0 0 0 + + + 0 + + 0 + 0
*Selected cell source: recently expired 11-cell panel. 
AHG = antihuman globulin.
Table 4. Case Study 3: Results of 11-cell antibody identification panel 
Cell 
no.
Rh Kell Duffy Kidd
Sex-
linked Lewis MNS P Lutheran
Test 
result
Rh D C E c e f Cw V K k Kpa Kpb Jsa Jsb Fya Fyb Jka Jkb Xga Lea Leb S s M N P1 Lua Lub AHG
1 R1wR1 + + 0 0 + 0 + 0 0 + 0 + 0 + + 0 0 + 0 0 + 0 + + + + 0 + 3+
2 R1R1 + + 0 0 + 0 0 0 + + 0 + / + + + + 0 + 0 + 0 + + + + 0 + 3+
3 R2R2 + 0 + + 0 0 0 0 0 + 0 + / + 0 + + + + 0 + 0 + + + + 0 + 0
4 R0r + 0 0 + + + 0 + 0 + 0 + / 0 0 0 + + 0 0 0 0 + + + s + + 3+
5 r′r 0 + 0 + + + 0 0 0 + 0 + / + 0 + + 0 + 0 + + + + + 0 0 + 3+
6 r″r 0 0 + + + + 0 0 + + 0 + / + 0 + + + + 0 + 0 + + + + 0 + 3+
7 rr 0 0 0 + + + 0 0 + + 0 + / + 0 + + 0 + + 0 + + + + + 0 + 3+
8 rr 0 0 0 + + + 0 0 0 + 0 + / + + + 0 + 0 0 + + 0 0 + 0 0 + 3+
9 rr 0 0 0 + + + 0 0 0 + 0 + / + + 0 0 + + 0 + 0 + + + + 0 + 3+
10 rr 0 0 0 + + + 0 0 0 + 0 + / + 0 + 0 + + 0 0 + 0 + 0 0 0 + 3+
11 R1R1 + + 0 0 + 0 0 0 0 + 0 + 0 + 0 + + 0 0 + 0 0 + 0 + 0 + + 3+
Patient’s cells 0
AHG = antihuman globulin.
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reacted preferentially with double-dose RBCs. It was likely 
because of dosage that anti-N was missed in the initial 11-
cell identification panel (cell number 3: M+N+). Nevertheless, 
anti-K and anti-Fya could not be excluded. Units that were 
e–N– were transfused with no adverse reaction.
Discussion
In this case, the extended-cell antibody identification panel 
played an important role by providing three R2R2 cells, which 
helped in identifying the additional antibody. But this testing 
was not complete because at least two antigen-positive and two 
antigen-negative cells were needed to confirm the specificity. 
A e– cell from an expired panel was used for confirmation. 
Selected cells from two different sources (an extended-cell 
antibody identification panel and a recently expired 11-cell 
identification panel) confirmed the antibody identification.
Determination of Antibody Titers 
Titration is an important part of prenatal testing in 
isoimmunized D– pregnant women. Titration is performed at 
regular intervals during pregnancy; the change in titer and/or 
score helps decide the need for intervention (i.e., intrauterine 
transfusion). The antibody titer is the reciprocal of the highest 
serum dilution that causes macroscopic agglutination when 
serial dilutions of an antibody are tested against selected 
RBCs. Titration is commonly performed for anti-D in Rh 
isoimmunized mothers, but many other unexpected antibodies 
are also responsible for severe hemolytic disease of the fetus 
and newborn and need monitoring by titration.
Case study 4
A D– pregnant woman with an obstetric history of only one 
living child (gravida 4, para 2) was found to be alloimmunized 
with three clinically significant unexpected antibodies: anti-D, 
anti-S, and anti-Jkb. Specific antibody titration monitoring 
was advised. To perform the titration of each specific antibody, 
selected cells were needed that were positive for one antigen 
and negative for the other two antigens.
Results
For titration of anti-D, a selected cell was chosen from 
an antibody identification panel that was D+, S–, Jk(b–) (cell 
number 4: R0r) (Table 7). For titration of anti-S, a selected cell 
was chosen from the same antibody identification panel that 
was S+, D–, Jk(b–) (cell number 9: rr). For titration of anti-
Jkb, selected cell number 21 from an extended-cell antibody 
identification panel (Table 8) was used that was Jk(b+), D–, 
S–. Titrations were performed and found to be 64 for anti-D, 
128 for anti-S, and 16 for anti-Jkb.
Discussion
In this case, selected cells for the titration of anti-D and 
anti-S were chosen from an in-date antibody identification 
panel, and an extended-cell antibody identification panel was 
used as a source of selected cells for the titration of anti-Jkb.
Table 6. Case Study 3: Results of testing with additional selected cell*
Cell 
no.
Rh Kell Duffy Kidd
Sex-
linked Lewis MNS P Lutheran
Test 
result
Rh D C E c e f Cw V K k Kpa Kpb Jsa Jsb Fya Fyb Jka Jkb Xga Lea Leb S s M N P1 Lua Lub AHG
3 R2R2 + 0 + + 0 0 0 0 0 + 0 + 0 + 0 + + + + 0 + + + 0 + 0 0 + 3+
*Selected cell source: extended-cell antibody identification panel. 
AHG = antihuman globulin.
Table 5. Case Study 3: Results of testing with selected cells*
Cell 
no.
Rh Kell Duffy Kidd
Sex-
linked Lewis MNS P Lutheran
Test 
result
Rh D C E c e f Cw V K k Kpa Kpb Jsa Jsb Fya Fyb Jka Jkb Xga Lea Leb S s M N P1 Lua Lub AHG
15 R2R2 + 0 + + 0 0 0 0 0 + 0 + 0 + + 0 + 0 + 0 + + + 0 + s 0 + 3+
16 R2R2 + 0 + + 0 0 0 0 0 + 0 + / + 0 + 0 + 0 0 0 + 0 + + + 0 + 0
17 R2R2 + 0 + + 0 0 0 0 0 + 0 + 0 + 0 + + + + + 0 + + + + + 0 + 0
*Selected cell source: extended-cell antibody identification panel. 
AHG = antihuman globulin.
IMMUNOHEMATOLOGY, Volume 33, Number 1, 2017 33
Use of selected cells in immunohematologic testing
Identification of Underlying Alloantibodies by 
Differential Adsorption
In WAIHA, autoantibodies may interfere in pre-
transfusion testing. These RBC autoantibodies present in the 
patient’s serum, potentially react with all cells on the antibody 
identification panel, giving a panreactive picture and making 
unexpected alloantibody identification complex. Many times, 
these patients are anemic, and there are not enough autologous 
RBCs available to perform autoadsorption, or the patient has 
been recently transfused (within 3 months), which precludes 
autoadsorption. In these cases, differential adsorption is used.
For this method, the patient’s serum sample is divided 
into three aliquots. Each aliquot is adsorbed with a different 
cell of known phenotype. Usually, one cell is R1R1, one is R2R2, 
and the third is rr. Among these three cells, one cell should be 
negative for Jka, another negative for Jkb, and the third negative 
for K. The cells should be treated with an enzyme to render 
them negative for antigens in the Duffy and MNS systems.10
Table 7. Case Study 4: Selected cells chosen for titration of anti-D and anti-S in the presence of multiple antibodies*
Cell 
no.
Rh Kell Duffy Kidd
Sex-
linked Lewis MNS P Lutheran
Rh D C E c e f Cw V K k Kpa Kpb Jsa Jsb Fya Fyb Jka Jkb Xga Lea Leb S s M N P1 Lua Lub
1 R1wR1 + + 0 0 + 0 + 0 0 + 0 + / + 0 + + + + 0 + 0 + + 0 + 0 +
2 R1R1 + + 0 0 + 0 0 0 0 + 0 + / + + + 0 + + 0 + + + + + 0 0 +
3 R2R2 + 0 + + 0 0 0 0 + + 0 + 0 + 0 + + + 0 0 + + 0 + 0 + 0 +
4 R0r + 0 0 + + + 0 + 0 + 0 + / + + 0 + 0 + 0 0 0 + + + + 0 +
5 r′r 0 + 0 + + + 0 0 0 + 0 + / + 0 + + + + 0 + 0 + + + + 0 +
6 r″r 0 0 + + + + 0 0 + + 0 + 0 + 0 + + + + + 0 + + + + + 0 +
7 rr 0 0 0 + + + 0 0 0 + 0 + 0 + 0 + + 0 0 0 + + + + 0 0 0 +
8 rr 0 0 0 + + + 0 0 0 + 0 + / + + + 0 + + + 0 + 0 0 + + 0 +
9 rr 0 0 0 + + + 0 0 0 + 0 + / + + 0 + 0 + 0 + + 0 + 0 + 0 +
10 rr 0 0 0 + + + 0 0 0 + 0 + / + 0 + + 0 + 0 0 + + 0 + + + +
11 R1wR1 + + 0 0 + 0 + 0 + + 0 + / + 0 + 0 + + + 0 + + + 0 + 0 +
*Selected cell source: in-date antibody identification panel.
Table 8. Case Study 4: Selected cells chosen for titration of anti-Jkb in the presence of multiple antibodies*
Cell 
no.
Rh Kell Duffy Kidd
Sex-
linked Lewis MNS P Lutheran
Rh D C E c e f Cw V K k Kpa Kpb Jsa Jsb Fya Fyb Jka Jkb Xga Lea Leb S s M N P1 Lua Lub
12 R2R2 + 0 + + 0 0 0 0 0 + 0 + / + 0 + + + + 0 + 0 + + 0 + 0 +
13 R2R2 + 0 + + 0 0 0 0 0 + 0 + + + + + 0 + + 0 + 0 + + + 0 0 +
14 R2R2 + 0 + + 0 0 0 + 0 + 0 + 0 + 0 + + + 0 0 + + 0 + 0 + 0 +
15 R0r + 0 0 + + + 0 + 0 + 0 + / + 0 0 + 0 + 0 0 0 + + + + 0 +
16 r′r 0 + 0 + + + 0 0 0 + 0 + / + 0 + + + + 0 + + + + + + + +
17 r″r 0 0 + + + + 0 0 0 + 0 + 0 + 0 + + 0 + + 0 0 + 0 + + 0 +
18 RzR1 + + + 0 + 0 0 0 + 0 + 0 + 0 + + 0 0 0 + + + + 0 0 0 +
19 R2r + 0 + + + + 0 0 0 + 0 + / + + + 0 + + + 0 + 0 0 + + 0 +
20 rr 0 0 0 + + + 0 0 0 + + + / + + 0 0 + + 0 + + 0 + 0 + 0 +
21 r′r 0 + 0 + + + 0 0 0 + 0 + / + 0 + 0 + + 0 + 0 + 0 + 0 0 +
22 R1R1 + + 0 0 + 0 0 0 + 0 0 + / + 0 + 0 + + + 0 + + + 0 + 0 +
*Selected cell source: extended-cell antibody identification panel.
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Case study 5
A patient with warm AIHA, whose autoantibody was 
causing agglutination with all 11 cells on the initial antibody 
identification panel, was admitted for symptomatic anemia. 
To identify or exclude alloantibodies being masked by the 
autoantibody, adsorption of the patient’s autoantibody was 
needed. Autoadsorption was not possible, since there was 
not enough blood sample available (patient’s hemoglobin was 
6 g/dL; normal for males >13 g/dL; females >12 g/dL), and 
there was history of recent transfusion (15 days earlier). An 
alloadsorption was planned. 
Results
R1R1, R2R2, and rr cells were identified. Among these three 
cells, R1R1 was negative for Jka and K, and rr was negative for 
Jkb. Finding R1R1 and rr RBCs was easy, but finding R2R2 
RBCs was difficult. R1R1 RBCs were obtained from a freshly 
phenotyped unit of blood, and R2R2 and rr RBCs were obtained 
from institutional rare donor inventory. After alloadsorption, 
anti-E was identified as an unexpected antibody, which was 
masked by the autoantibody reacting at 37°C (Table 9).
Discussion
In this case, selected cells were used as a source for 
autoantibody adsorption. These selected cells were obtained 
from phenotyped donor units and institutional rare donor 
inventory, respectively.
Conclusions
Selected cells have several important applications in 
immunohematology, such as confirming or eliminating 
the specificity of an antibody when multiple antibodies are 
suspected in routine testing, titrating antibodies in pregnant 
women, and performing a differential adsorption for patients 
with warm AIHA. Any cell from an in-date or out-dated, 11-
cell or extended-cell panel can be used as a selected cell.
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Table 9. Case Study 5: Selected cells chosen for differential adsorption
Cell no.
Rh Kell Duffy Kidd Lewis MNS
Rh D C E c e K k Fya Fyb Jka Jkb Lea Leb M N S s
1 R1R1 + + 0 0 + 0 + + 0 0 + 0 + 0 + 0 +
2 R2R2 + 0 + + 0 0 + + 0 + + 0 + + + + +
3 rr 0 0 0 + + + + 0 + + 0 + 0 + 0 0 +
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